Curriculum Vitae

Dr. Stephen A. Mangar

MB ChB MRCP FRCR MSc MD.

Consultant Clinical Oncologist and Honorary Senior Lecturer

June 2010

 

CONTENTS

Personal details

Academic qualifications

Present employment

Associations

Research

Publications

Audit

Presentations

Courses and meetings attended

Employment history

Interests

 

 

PERSONAL DETAILS

NAME: Stephen Anthony Mangar
TELEPHONE: 0127 6857980
E-MAIL: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
YEAR OF BIRTH: 1971
NATIONALITY: British
MARITAL STATUS: Married

 

ACADEMIC QUALIFICATIONS

MD - (University of London)- London – 2008

FRCR- (Royal College of Radiologists) - London- May 2003.

MSc - (University of Manchester) Clinical Oncology- Dec 2002

MRCP - (Royal College of Physicians)- London- Feb 1999

MB ChB - (University of Liverpool) -Jun 1994.

GMC Reg No. 4123365. Certificate of Completion of Training awarded- 18th May 2006

Good Clinical Practice training- Royal College of Physicians - Nov 2008

 

PRESENT EMPLOYMENT

Consultant Clinical Oncologist, and Honorary Senior Lecturer, Imperial College Healthcare NHS Trust, Hammersmith site.

Lead for uro-oncology North West London Hospitals NHS Trust

Special Interests: Prostate, Bladder and  Lung cancers
Other interests: Breast and Gastrointestinal cancers. Late effects of radiation treatment.

Dept. of Radiotherapy
Imperial College Healthcare NHS Trust, Hammersmith Hospital
Du Cane Road, London ,W12 OSH
Tel- 0208 383 8132, Fax-0208 3833054

 

ASSOCIATIONS

European Society for Therapeutic Radiology and Oncology (ESTRO)

American Association for Cancer Research (AACR)

British Uro-Onoclogy Group (BUG)

 

RESEARCH

My stimulus for uro-oncology comes mainly from my initial desire to pursue brachytherapy for prostate cancer. As part of my MSc, I spent two years investigating permanent seed implants, and reporting our initial experiences at the Christie hospital. Following this I undertook an MD investigating methods of improving radiotherapy outcomes for bladder cancer.

Msc Clinical Oncology- The University of Manchester

This was a modular course taught over two years, with also a research component in the form of a project.

Essays completed-

1) Molecular Aspects of Breast Cancer- Oct 1999.

2) Novel Therapies for Metastatic Prostate Cancer-Oct 2000.

Project Dissertation- Prostate Brachytherapy- An overview and the Christie experience

MD  Clinical Oncology- The University of London

Registered June 2004, completed February 2006.

Thesis title:
Optimising radiotherapy for bladder cancer- Implementing strategies based on an understanding of organ motion and on-treatment verification.

This work involved starting a mainly clinical project from new, and recruiting patients required a good understanding of standard operating procedures, and conducted in accordance with EU guidelines for Good Clinical Practice (GCP).


Trial Protocols written and scientifically and ethically approved:

  1. Evaluating the use of ultrasound in monitoring changes in volume and position of the bladder in patients undergoing radical radiotherapy for bladder cancer (BUMPER)
    Study Protocol Number: CCR 2535
  2. Assessing the feasibility of inserting gold seeds into the bladder wall to act as markers for improving the accuracy of bladder radiotherapy.
    Study Protocol Number: CCR 2490
  3. Predictive Organ Localisation (POLO)- Evaluating the changes in bladder shape and position over a time period using Magnetic Resonance (MR) scanning.
    Study Protocol Number: CCR 2563
  4. Establishing the use of 11C Choline PET-CT in the detection of nodal disease to improve target delineation for delivery of conformal radiotherapy. Ref 07/H707/151
  5. TACTICAL-  A phase I/II randomised study of TArceva (Erlotonib), used Concurrently with Thoracic Irradiation in patients deteCted with Advanced non -small cell lung Cancer. Ref 08/H1208 /41
  6. High dose rate brachytherapy boost following external beam radiotherapy for high risk localized prostate cancer- Ref 07/H0707/111
  7. Pilot study of  single phase prostate and pelvis IMRT for treating high risk prostate cancer- initial experience presented UKRO 2009.

Clinical Trials recruiting -Role as Co-investigator

  1. CHHIP- prostate cancer radiotherapy trial using IMRT, -  recruiting since  December 2008
  2. BC2001- Bladder cancer radiotherapy trial, - recruitment now completed
  3. DA vs DAS- investigating the use of stilboestrol in hormone refractory prostate cancer- recruitment now completed
  4. BTOG-2- lung cancer chemotherapy- recruiting since July 2008
  5. CONVERT- radiotherapy for small cell lung cancer trial- approved for recruitment August 2008
  6. Identifying molecular biomarkers for the development of cancers and their response to treatment using spectroscopic analysis- scientifically and ethically approved- due to start June 2009
  7. PROCLAIM- lung chemoradiotherapy study.

Role as Principal Investigator for studies at Hammersmith Hospital

  1. Establishing the use of 11C Choline PET-CT in the detection of nodal disease to improve target delineation for delivery of conformal radiotherapy.
  2. Prostate fiducial marker pilot study.
  3. The use of high dose rate brachytherapy boost in combination with external beam radiotherapy - a method of radiation dose escalation in patients with high risk localised prostate cancer.
  4. TACTICAL-  A phase I/II randomised study of TArceva (Erlotonib), used Concurrently with Thoracic Irradiation in patients deteCted with Advanced non -small cell lung Cancer.

 

PUBLICATIONS

The majority of my publications have focussed on Urology, though I have previously written on topics ranging from head and neck to oesophageal cancer. Of particular note – Technological advances in radiotherapy treatment for localized prostate cancer is one of the top 12 most downloadable article, and Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer was in the top 7 most downloadable article for the green journal on Mar 2006.

Reviews:

Mangar SA, Wylie JP, Logue JP.
Prostate Brachytherapy- A review
CME (Cancer Medicine) 2003;2(1):3-9

Mangar SA, Coote J, Faivre-Finn C, and Burt PA.
Oesophageal cancer an update on investigations and management.
CME (Cancer Medicine) 2004;2(2):55-64

Mangar SA, Huddart RA, Parker CC, Dearnaley DP, Khoo VS, and Horwich A.
Review article- Technological advances in radiotherapy for the treatment of localized  prostate cancer.
European Journal of Cancer 2005; 41:908-921

Mangar SA, Khoo VS
Radiotherapy for bladder cancer: Improving clinical outcomes.
British Journal of Cancer Management 2005; 1(4):4-7

 

Original Research:

Mangar SA, Logue JP, Shanks JH, Cooper RA, Cowan RA, and Wylie JP.
Small cell carcinoma of the urinary bladder- ten year experience.
Clinical Oncology  2004;16(8):523-527

Mangar SA, Slevin NJ, Mais KL, and Sykes AJ.
Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer. Radiother Oncol 2006, 78(2):152-8.

McNair H, Coffey J, Mangar SA, et al.
A comparison of CT and ultrasound based images to localize the prostate  for external beam radiotherapy. Int J Radiat Oncol Biol Phys 2006, 63(3):678-87.

Mangar SA, Foo K, Norman A, Shaidi M et al.
Evaluating the effect of reducing the high dose volume on toxicity of radiotherapy in the treatment of bladder cancer. Clinical Oncology 2006, 18(6):466-473.

Mangar SA, Coffey J, McNair H, Hansen VN, et al. Prostate radiotherapy: Evaluating the effect of bladder and rectal changes on prostate movement. A CT study. Trends in Medical Research 2006, 1(1):55-65.

Mangar SA, MR Sydes, Tucker HL, Coffey J. et al.
Evaluating the relationship between erectile dysfunction and dose received by the penile bulb in patients undergoing conformal radiotherapy for prostate cancer: Analysis of data from the MRC RT01 dose escalation trial.
Accepted for publication Radiother Oncol 2006, 80:355-362.

Mangar SA, Thompson A, Miles E, Huddart R, et al
The feasibility of using gold seeds to act as fiducial markers for bladder localisation during radiotherapy. Accepted for publication  British Journal of Radiology 2007, 80(952):279-283.

Jackson ASN, Mangar SA, Sohaib SA, et al
Distortion Corrected T2 weighted MRI: A novel approach to prostate radiotherapy planning. British Journal of Radiology  2007, 80(959): 926-33.

Mangar SA, Scurr E, Huddart RA, Sohaib SA, Horwich A, Dearnaley DP, Khoo VS. Assessing intra-fractional bladder motion using cine MRI, as initial methodology for predictive organ localisation (POLO) in radiotherapy for bladder cancer. Radiother Oncol. 2007, 85(2): 207-14

Mangar SA, Miller NR,  Norman A, Hansen V,  Foo K,  McNair H, et al.
Evaluating interfractional changes in volume and position during bladder radiotherapy and the impact of volume limitation as a method of reducing the internal margin of the Planning Target Volume. Clinical Oncology 2008, 20:698-704

 

Abstracts from Oral and Poster presentations at National and International meetings

My most important presentation has been at ASTRO, Denver, 2005 giving an oral presentation on the effect radiation dose to the penile bulb and erectile dysfunction.


Assessment of cardiac volume in tangential irradiation to the chest wall following mastectomy
Abstract- Clinical Oncology 2002; 14: 174-177

Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer – BOA, Edinburgh Sept 2004.
Abstract- Clinical Oncology 2004; 16(6): S25. (P1.05)

Evaluating the accuracy of ultrasound localization for positioning prostate cancer patients for external beam radiotherapy- poster presentation –ESTRO 2004. Radiother Oncol 2004;73(1):S288-289 (P662)

Evaluating the effect of changes in rectal and bladder volumes on prostate movement-  poster presentation –ESTRO 2004. Radiother Oncol 2004;73(1):S455 (P1083)

Prostate radiotherapy- Assessing the use of adaptive margins to the prostate to account for prostate movement- A CT study- oral presentation - British Prostate Group Meeting, University of York, April 2005.

Evaluating the relationship between erectile dysfunction and dose received by the penile bulb in patients undergoing conformal radiotherapy for prostate cancer: Analysis of data from the MRC RT01 dose escalation trial. Oral presentation ASTRO (Denver) Oct 2005. Int J. Radiat. Oncol. Biol. Phys 2005; 63(2S1):S126.

The feasibility of using gold seeds to act as fiducial markers for bladder localisation during radiotherapy. Oral presentation UKRC, Birmingham 16TH May 2006.

Assessing intra-fractional bladder motion using cine MRI, as initial methodology for predictive organ localisation (POLO) in radiotherapy for bladder cancer- Oral presentation- ESTRO 2006. Radiother Oncol 2006 81 (S1): 249, S99.

Optimising radiotherapy for seminoma using fields based on surgical templates for retroperitoneal lymph node dissection. Poster presentation- ESTRO 2006. Radiother Oncol 2006 81 (S1): 1315, S99.

Early experience of simultaneous integrated boost IMRT to the prostate and pelvic lymph nodes for high risk prostate cancer- accepted for oral presentation UKRO 2009

Initial experience with extended laparoscopic extra-peritoneal pelvic lymphadenectomy (eLPL) to stratify patients with prostate cancer for whole pelvic radiotherapy- accepted for poster presentation ESTRO (Barcelona) 2010

Determination of pelvic node status in patients with high risk localised or locally advanced prostate cancer by [11C] choline PET-CT. Accepted for presentation ASCO 2010

Optimising Image Guided Radiotherapy (IGRT) for prostate cancer: A feasibility study using ACCULOC® with implanted fiducial markers. Accepted for poster presentation ESTRO (Barcelona) 2010

 

AUDIT


July 2001-East Lancashire Breast Forum - An audit of the treatment of pre-menopausal women with breast cancer

March 2003-Christie Hospital Audit- Radiotherapy management of Glioblastoma Multiforme

Feb 2006- Royal Marsden Hospital Audit –Auditing consultant input on new patient referrals.

March 2007- Hammersmith Hospital NHS Trust lung cancer audit- Auditing the use of gemcitabine carboplatin chemotherapy in patients with non small cell lung cancer: determining the rates of myelosupression and thrombocytopaenia

In progress: Radiation proctitis audit

 

PRESENTATIONS

March 2001
North West Urological Association-Prostate Brachytherapy- The Christie Experience
The Patterson Institute, Manchester

February 2002
Breast Cancer : Advances in radiotherapy planning and treatment.
Royal Marsden Hospital- Institute of Physics, Engineering and Medicine

Nov 2005
Invited speaker- Royal Marsden Hospital-Evaluating the relationship between erectile dysfunction and dose received by the penile bulb in patients undergoing conformal radiotherapy for prostate cancer: Analysis of data from the MRC RT01 dose escalation trial.

Nov 2005
Academic Meeting- Royal Marsden Hospital- An update on prostate cancer management- highlights from ASTRO 2005.

Dec 2005
CHHIP investigator meeting- Royal Marsden Hospital Conference Centre
Implementing the penile bulb as an avoidance structure: implications for the CHHIP trial

Nov 2008
Grand Round presentation: Central Middlesex Hospital
Technological advances in prostate cancer management


22nd April 2010
Invited Speaker: British Institute of Radiology: Imaging and management of male urogenital disorders. The rationale for high dose rate brachytherapy in the treatment of prostate cancer.


COURSES AND MEETINGS ATTENDED

November 2001- European Institute of Healthcare- Barcelona , Symposium on    Cancer Prevention

May 2002- FRCR 2 Course-Edinburgh

July 2002- Investigator meeting- Tirapazimine with chemoradiotherapy for head and neck cancer- launch of phase 3 trial

June 2004- Methods in Clinical Research –  6th FECS/AACR/ASCO, Flims, Switzerland.

March 2004- PET symposium- Royal College of Physicians, London

Sept 2004- British Oncological Association, Edinburgh.

Nov 2004 – ESTRO- Amsterdam

April 2005- British Prostate Group meeting, University of York

Nov 2005– ASTRO- Denver

Jan 2006– Medical Communication Skills course- Hammersmith Hospital, London

Sept 2006- British Uro-Oncology Group meeting, Eastwood, Nottingham

October 2006- ESTRO- Liepzig, Germany

February 2007- ASCO –Prostate Symposium

Jan 2007- HDR prostate brachytherapy conference – Athens, Greece

May 2007-  AUA (American Urological Association) – Anaheim, California

August 2007- World Lung Conference- Seoul, korea

June 2008- ASCO-Chicago, USA

 


EMPLOYMENT  HISTORY

Aug 1994-Aug 1995 Pre Registration House Officer
Royal Liverpool University Hospital
Prescot Street
Liverpool L7 8XP
Tel No. 0151 706 2000.
Aug 1995-Aug 1996 SENIOR HOUSE OFFICER
General Medicine/ Cardiology
Royal Liverpool University Hospital
Aug 1996-Aug 1997 SENIOR HOUSE OFFICER
Haematology
Royal Free Hospital
Hampstead
London NW3
Tel No. 0207 704 0500
Aug 1997- Feb 1998 SENIOR HOUSE OFFICER
Accident and Emergency
Royal Liverpool University Hospital
Mar 1998- Aug 1999 ONCOLOGY MEDICAL OFFICER
Cromwell Hospital
London SW5 0TU
Aug 1999- Jun 2006 SPECIALIST REGISTRAR
Clinical Oncology
Christie Hospital, Manchester.


Out of program experience

Jan 2004-Feb 2006 MD- Clinical Research Fellow
Academic Department of Urology
Royal Marsden Hospital
Downs Road
Sutton SM2 5PT
Tel: 0208 642 6011

 

OTHER INTERESTS

-Swimming, musical instrument- guitar, ballroom dancing
-Walking. Organiser of:

  1. The River Thames Coastal Pathway -August 1989 (funds to Cancer Research Campaign)
  2. The Pembrokeshire Pathway -August 1991(funds to Cancer Research Campaign)
  3. Took part in the Nijmegan Charity Walk-May 1992 (on behalf of Royal Army Medical Corp. 208 Field Hospital)